Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from INSPIRE

Dow Jones Falls After Inflation Survey Data; Lyft Crashes 35% On Earnings Miss

The Dow Jones Industrial Average fell Friday after preliminary inflation survey data from the University of Michigan. Lyft crashed on weak Q4 results.

Investors Business Daily

How IBD Stock Of The Day Inspire Medical Systems Won A Breakout

Inspire is Wednesday's IBD Stock Of The Day. The sleep apnea expert reported massive sales growth, leading shares to break out.

Investors Business Daily

A year without Lily, mum marks anniversary of Perth teen's passing

Lily Douglas from Perth danced her way to heaven a year ago after a courageous battle with cancer but her name will live on with plans for a respite retreat to help families with sick children.

Daily Record

From analysis to the latest developments in health,
read the most diverse news in one place.

Zynerba Pharmaceuticals R&D Expenses For Q3 Reach $5M, Here Are The Details

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), released financial results for the third quarter ended September 30, 2022. Q3 2022 Financial Highlights

Benzinga

Tragedy of British Army veteran haunted by serving in Iraq and Afghanistan found dead at home

Ben Riches was just 30 when he passed away

Manchester Evening News

Terrified mum-of-four suffers flashbacks after being put on Covid ventilator while heavily pregnant

Mechelle Smith insists doctors saved her and her son after she became seriously unwell.

Daily Record

DST’s decision to scrap KVPY disappoints teachers, aspirants in government schools

The decision of Department of Science and Technology, New Delhi, to scrap Kishore Vaigyanik Protsahan Yojna (KVPY) fellowship from this year has caused disappointment among school teachers who were keenly anticipating its conduct in Tamil for the convenience of the students following the Supreme Court's intervention last year.

The Hindu

Read news from The Economist, FT, and more,
with one subscription

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga

Glasgow residential care group completes shareholder buyout

ThinCats provides financial backing to Inspire Scotland to complete transaction

Insider UK

Christian funds in quandary after companies support abortion rights

For money managers who invest billions of dollars in accordance with faith-based teachings, the toppling of the half-century-old US ruling that protected abortion rights was a moment of celebration.

Tribune News Service

Zynerba Pharmaceuticals Reveals Positive Results From Phase 2 INSPIRE Trial Of Zygel In 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) revealed positive top line results from the exploratory, open label Phase 2 INSPIRE trial. Based on the positive Phase 2 data, the company will request a meeting with the U.S.

Benzinga

Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial

Capricor Therapeutics Inc (NASDAQ: CAPR) announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for hospitalized COVID-19 patients.

Benzinga

Zynerba Pharmaceuticals Reveals Lower Net Loss For Q4 And Full Year 2021

Manufacturer of transdermal cannabinoid therapies for neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) reported Tuesday financial results for the fourth quarter and full year ended December 31, 2021.

Benzinga

Zynerba Pharmaceuticals Completes Enrollment For CBD Transdermal Trial For 22q Deletion Syndrome

Manufacturer of transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, Zynerba Pharmaceuticals, Inc.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of Alofisel (darvadstrocel).

The Hindu

INSPIRESat-1 satellite healthy: IIST

It would study ionosphere dynamics and sun's coronal heating processes

The Hindu

IIST has a role in ISRO’s first launch of the year

INSPIRESat-1 one of the three satellites to be launched aboard PSLV C-52 tomorrow

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Amyotrophic lateral sclerosis

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.